LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 1207

Search options

  1. Article ; Online: Pharmacological agents for procedural sedation and analgesia in the emergency department and intensive care unit: a systematic review and network meta-analysis of randomised trials.

    Sharif, Sameer / Kang, Jasmine / Sadeghirad, Behnam / Rizvi, Fayyaz / Forestell, Ben / Greer, Alisha / Hewitt, Mark / Fernando, Shannon M / Mehta, Sangeeta / Eltorki, Mohamed / Siemieniuk, Reed / Duffett, Mark / Bhatt, Maala / Burry, Lisa / Perry, Jeffrey J / Petrosoniak, Andrew / Pandharipande, Pratik / Welsford, Michelle / Rochwerg, Bram

    British journal of anaesthesia

    2024  Volume 132, Issue 3, Page(s) 491–506

    Abstract: Background: We aimed to evaluate the comparative effectiveness and safety of various i.v. pharmacologic agents used for procedural sedation and analgesia (PSA) in the emergency department (ED) and ICU. We performed a systematic review and network meta- ... ...

    Abstract Background: We aimed to evaluate the comparative effectiveness and safety of various i.v. pharmacologic agents used for procedural sedation and analgesia (PSA) in the emergency department (ED) and ICU. We performed a systematic review and network meta-analysis to enable direct and indirect comparisons between available medications.
    Methods: We searched Medline, EMBASE, Cochrane, and PubMed from inception to 2 March 2023 for RCTs comparing two or more procedural sedation and analgesia medications in all patients (adults and children >30 days of age) requiring emergent procedures in the ED or ICU. We focused on the outcomes of sedation recovery time, patient satisfaction, and adverse events (AEs). We performed frequentist random-effects model network meta-analysis and used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach to rate certainty in estimates.
    Results: We included 82 RCTs (8105 patients, 78 conducted in the ED and four in the ICU) of which 52 studies included adults, 23 included children, and seven included both. Compared with midazolam-opioids, recovery time was shorter with propofol (mean difference 16.3 min, 95% confidence interval [CI] 8.4-24.3 fewer minutes; high certainty), and patient satisfaction was better with ketamine-propofol (mean difference 1.5 points, 95% CI 0.3-2.6 points, high certainty). Regarding AEs, compared with midazolam-opioids, respiratory AEs were less frequent with ketamine (relative risk [RR] 0.55, 95% CI 0.32-0.96; high certainty), gastrointestinal AEs were more common with ketamine-midazolam (RR 3.08, 95% CI 1.15-8.27; high certainty), and neurological AEs were more common with ketamine-propofol (RR 3.68, 95% CI 1.08-12.53; high certainty).
    Conclusion: When considering procedural sedation and analgesia in the ED and ICU, compared with midazolam-opioids, sedation recovery time is shorter with propofol, patient satisfaction is better with ketamine-propofol, and respiratory adverse events are less common with ketamine.
    MeSH term(s) Adult ; Child ; Humans ; Propofol/adverse effects ; Midazolam/adverse effects ; Ketamine/adverse effects ; Network Meta-Analysis ; Pain/drug therapy ; Analgesics, Opioid/therapeutic use ; Analgesia ; Emergency Service, Hospital ; Intensive Care Units ; Conscious Sedation/adverse effects ; Conscious Sedation/methods ; Randomized Controlled Trials as Topic
    Chemical Substances Propofol (YI7VU623SF) ; Midazolam (R60L0SM5BC) ; Ketamine (690G0D6V8H) ; Analgesics, Opioid
    Language English
    Publishing date 2024-01-06
    Publishing country England
    Document type Meta-Analysis ; Systematic Review ; Journal Article ; Review
    ZDB-ID 80074-0
    ISSN 1471-6771 ; 0007-0912
    ISSN (online) 1471-6771
    ISSN 0007-0912
    DOI 10.1016/j.bja.2023.11.050
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.

    Yi, Tae Won / Wong, Michelle M Y / Neuen, Brendon L / Arnott, Clare / Poirier, Paul / Seufert, Jochen / Slee, April / Rapattoni, Wally / Ang, Fernando G / Wheeler, David C / Mahaffey, Kenneth W / Perkovic, Vlado / Levin, Adeera

    Diabetes, obesity & metabolism

    2023  Volume 25, Issue 7, Page(s) 2043–2047

    MeSH term(s) Humans ; Canagliflozin/therapeutic use ; Kidney ; Cardiovascular System ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/drug therapy ; Renal Insufficiency, Chronic/chemically induced ; Peripheral Arterial Disease/complications ; Peripheral Arterial Disease/drug therapy ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/chemically induced ; Cardiovascular Diseases/complications ; Cardiovascular Diseases/drug therapy ; Cardiovascular Diseases/prevention & control
    Chemical Substances Canagliflozin (0SAC974Z85)
    Language English
    Publishing date 2023-04-24
    Publishing country England
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 1454944-x
    ISSN 1463-1326 ; 1462-8902
    ISSN (online) 1463-1326
    ISSN 1462-8902
    DOI 10.1111/dom.15065
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis.

    Nanzer, Alexandra M / Maynard-Paquette, Anne-Catherine / Alam, Vardah / Green, Linda / Thomson, Louise / Lam, Jodie / Fernandes, Mariana / Roxas, Cris / d'Ancona, Grainne / Hearn, Andrew / Gates, Jessica / Agarwal, Sangita / Kent, Brian D / Fernando, Michelle / D'Cruz, David P / Hopkins, Claire / Ismail, Tevfik F / Dhariwal, Jaideep / Jackson, David J

    The journal of allergy and clinical immunology. In practice

    2024  Volume 12, Issue 3, Page(s) 724–732

    Abstract: Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a multisystemic disease characterized by eosinophilic tissue inflammation. Benralizumab, an anti-IL-5 receptor (anti-IL-5R) monoclonal antibody, induces rapid depletion of eosinophils; ... ...

    Abstract Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a multisystemic disease characterized by eosinophilic tissue inflammation. Benralizumab, an anti-IL-5 receptor (anti-IL-5R) monoclonal antibody, induces rapid depletion of eosinophils; its longer-term effect in EGPA is unknown.
    Objective: To assess the real-world effectiveness and clinical remission rates of anti-IL-5R therapy in EGPA.
    Methods: We performed a retrospective cohort analysis of patients with EGPA, who commenced treatment with benralizumab. Clinical remission, assessed at 1 year and 2 years after the initiation of benralizumab, was defined as an absence of active vasculitis (Birmingham Vasculitis Activity Score of 0) and an oral corticosteroid (OCS) dose of ≤4 mg/d of prednisolone. "Super-responders" were defined as patients in remission and free of any significant relapses (asthma or extrapulmonary) over the preceding 12 months. The corticosteroid-sparing capacity of benralizumab, patient-reported outcome measures, and characteristics associated with clinical remission and super-responder status were also analyzed.
    Results: A total of 70 patients completed at least 1 year of treatment with benralizumab, of whom 53 completed 2 years. Of 70 patients, 47 (67.1%) met the definition for clinical remission at 1 year, with a similar proportion in remission at 2 years. Excluding asthma-related relapses, 61 of 70 (87.1%) patients were relapse free at 1 year, and of the 53 who completed 2 years, 45 (84.9%) were relapse free. A total of 67.9% of patients no longer needed any OCS for disease control. No significant difference was seen between antineutrophilic cytoplasmic antibody (ANCA)-positive and ANCA-negative subgroups.
    Conclusions: In this real-world setting of patients with EGPA, treatment with benralizumab was well tolerated and resulted in corticosteroid-free clinical remission for the majority of patients.
    MeSH term(s) Humans ; Churg-Strauss Syndrome/drug therapy ; Granulomatosis with Polyangiitis/drug therapy ; Antibodies, Antineutrophil Cytoplasmic ; Retrospective Studies ; Asthma/drug therapy ; Adrenal Cortex Hormones/therapeutic use ; Eosinophilia ; Recurrence ; Antibodies, Monoclonal, Humanized
    Chemical Substances benralizumab (71492GE1FX) ; Antibodies, Antineutrophil Cytoplasmic ; Adrenal Cortex Hormones ; Antibodies, Monoclonal, Humanized
    Language English
    Publishing date 2024-01-09
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2843237-X
    ISSN 2213-2201 ; 2213-2198
    ISSN (online) 2213-2201
    ISSN 2213-2198
    DOI 10.1016/j.jaip.2024.01.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: The role of cardiovascular magnetic resonance in the evaluation of acute myocarditis and inflammatory cardiomyopathies in clinical practice - a comprehensive review.

    Ismail, Tevfik F / Hua, Alina / Plein, Sven / D'Cruz, David P / Fernando, Michelle M A / Friedrich, Matthias G / Zellweger, Michael J / Giorgetti, Assuero / Caobelli, Federico / Haaf, Philip

    European heart journal. Cardiovascular Imaging

    2022  Volume 23, Issue 4, Page(s) 450–464

    Abstract: Inflammatory cardiomyopathy (I-CMP) is defined as myocarditis in association with cardiac dysfunction and/or ventricular remodelling. It is characterized by inflammatory cell infiltration into the myocardium and has heterogeneous infectious and non- ... ...

    Abstract Inflammatory cardiomyopathy (I-CMP) is defined as myocarditis in association with cardiac dysfunction and/or ventricular remodelling. It is characterized by inflammatory cell infiltration into the myocardium and has heterogeneous infectious and non-infectious aetiologies. A complex interplay of genetic, autoimmune, and environmental factors contributes to the substantial risk of deteriorating cardiac function, acute heart failure, and arrhythmia as well as chronic dilated cardiomyopathy and its sequelae. Multi-parametric cardiovascular magnetic resonance (CMR) imaging is sensitive to many tissue changes that occur during myocardial inflammation, regardless of its aetiology. In this review, we summarize the various aetiologies of I-CMP and illustrate how CMR contributes to non-invasive diagnosis.
    MeSH term(s) Humans ; Cardiomyopathies/pathology ; Cardiomyopathy, Dilated ; Heart ; Magnetic Resonance Imaging ; Magnetic Resonance Spectroscopy ; Myocarditis/diagnostic imaging ; Myocardium/pathology
    Language English
    Publishing date 2022-02-16
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2638345-7
    ISSN 2047-2412 ; 2047-2404
    ISSN (online) 2047-2412
    ISSN 2047-2404
    DOI 10.1093/ehjci/jeac021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review.

    Haddad, Robert / Elisei, Rossella / Hoff, Ana O / Liu, Zhiyan / Pitoia, Fabian / Pruneri, Giancarlo / Sadow, Peter M / Soares, Fernando / Turk, Andrew / Williams, Michelle D / Wirth, Lori J / Cabanillas, Maria E

    JAMA oncology

    2023  Volume 9, Issue 8, Page(s) 1132–1141

    Abstract: Importance: Thyroid epithelial malignant neoplasms include differentiated thyroid carcinomas (papillary, follicular, and oncocytic), follicular-derived high-grade thyroid carcinomas, and anaplastic and medullary thyroid carcinomas, with additional rarer ...

    Abstract Importance: Thyroid epithelial malignant neoplasms include differentiated thyroid carcinomas (papillary, follicular, and oncocytic), follicular-derived high-grade thyroid carcinomas, and anaplastic and medullary thyroid carcinomas, with additional rarer subtypes. The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions has fostered developments in precision oncology, with the approval of tropomyosin receptor kinase inhibitors (larotrectinib and entrectinib) for patients with solid tumors, including advanced thyroid carcinomas, harboring NTRK gene fusions.
    Observations: The relative rarity and diagnostic complexity of NTRK gene fusion events in thyroid carcinoma present several challenges for clinicians, including variable access to robust methodologies for comprehensive NTRK fusion testing and poorly defined algorithms of when to test for such molecular alterations. To address these issues in thyroid carcinoma, 3 consensus meetings of expert oncologists and pathologists were convened to discuss diagnostic challenges and propose a rational diagnostic algorithm. Per the proposed diagnostic algorithm, NTRK gene fusion testing should be considered as part of the initial workup for patients with unresectable, advanced, or high-risk disease as well as following the development of radioiodine-refractory or metastatic disease; testing by DNA or RNA next-generation sequencing is recommended. Detecting the presence of NTRK gene fusions is important to identify patients eligible to receive tropomyosin receptor kinase inhibitor therapy.
    Conclusions and relevance: This review provides practical guidance for optimal integration of gene fusion testing, including NTRK gene fusion testing, to inform the clinical management in patients with thyroid carcinoma.
    MeSH term(s) Humans ; Neoplasms/drug therapy ; Receptor, trkA/genetics ; Receptor, trkA/therapeutic use ; Tropomyosin/genetics ; Tropomyosin/therapeutic use ; Iodine Radioisotopes/therapeutic use ; Oncogene Proteins, Fusion/genetics ; Precision Medicine ; Thyroid Neoplasms/diagnosis ; Thyroid Neoplasms/drug therapy ; Thyroid Neoplasms/genetics ; Gene Fusion ; Protein Kinase Inhibitors/therapeutic use
    Chemical Substances Receptor, trkA (EC 2.7.10.1) ; Tropomyosin ; Iodine Radioisotopes ; Oncogene Proteins, Fusion ; Protein Kinase Inhibitors
    Language English
    Publishing date 2023-06-08
    Publishing country United States
    Document type Review ; Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2023.1379
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Corrigendum to "Internal dose of vanadium in rats following repeated exposure to vanadyl sulfate and sodium orthovanadate via drinking water" [Toxicology and Applied Pharmacology 412 (2021) 115395].

    Harrington, James M / Haines, Laura G / Levine, Keith E / Liyanapatirana, Chamindu / Essader, Amal S / Fernando, Reshan A / Robinson, Veronica G / Roberts, Georgia K / Stout, Matthew D / Hooth, Michelle J / Waidyanatha, Suramya

    Toxicology and applied pharmacology

    2021  Volume 423, Page(s) 115546

    Language English
    Publishing date 2021-04-24
    Publishing country United States
    Document type Published Erratum
    ZDB-ID 204477-8
    ISSN 1096-0333 ; 0041-008X
    ISSN (online) 1096-0333
    ISSN 0041-008X
    DOI 10.1016/j.taap.2021.115546
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: A centronuclear myopathy-causing mutation in dynamin-2 disrupts neuronal morphology and excitatory synaptic transmission in a murine model of the disease.

    Arriagada-Diaz, Jorge / Flores-Muñoz, Carolina / Gómez-Soto, Bárbara / Labraña-Allende, Marjorie / Mattar-Araos, Michelle / Prado-Vega, Lorena / Hinostroza, Fernando / Gajardo, Ivana / Guerra-Fernández, María José / Bevilacqua, Jorge A / Cárdenas, Ana M / Bitoun, Marc / Ardiles, Alvaro O / Gonzalez-Jamett, Arlek M

    Neuropathology and applied neurobiology

    2023  Volume 49, Issue 4, Page(s) e12918

    Abstract: Aims: Dynamin-2 is a large GTPase, a member of the dynamin superfamily that regulates membrane remodelling and cytoskeleton dynamics. Mutations in the dynamin-2 gene (DNM2) cause autosomal dominant centronuclear myopathy (CNM), a congenital ... ...

    Abstract Aims: Dynamin-2 is a large GTPase, a member of the dynamin superfamily that regulates membrane remodelling and cytoskeleton dynamics. Mutations in the dynamin-2 gene (DNM2) cause autosomal dominant centronuclear myopathy (CNM), a congenital neuromuscular disorder characterised by progressive weakness and atrophy of the skeletal muscles. Cognitive defects have been reported in some DNM2-linked CNM patients suggesting that these mutations can also affect the central nervous system (CNS). Here we studied how a dynamin-2 CNM-causing mutation influences the CNS function.
    Methods: Heterozygous mice harbouring the p.R465W mutation in the dynamin-2 gene (HTZ), the most common causing autosomal dominant CNM, were used as disease model. We evaluated dendritic arborisation and spine density in hippocampal cultured neurons, analysed excitatory synaptic transmission by electrophysiological field recordings in hippocampal slices, and evaluated cognitive function by performing behavioural tests.
    Results: HTZ hippocampal neurons exhibited reduced dendritic arborisation and lower spine density than WT neurons, which was reversed by transfecting an interference RNA against the dynamin-2 mutant allele. Additionally, HTZ mice showed defective hippocampal excitatory synaptic transmission and reduced recognition memory compared to the WT condition.
    Conclusion: Our findings suggest that the dynamin-2 p.R465W mutation perturbs the synaptic and cognitive function in a CNM mouse model and support the idea that this GTPase plays a key role in regulating neuronal morphology and excitatory synaptic transmission in the hippocampus.
    MeSH term(s) Animals ; Mice ; Disease Models, Animal ; Dynamin II/genetics ; Dynamin II/metabolism ; Muscle, Skeletal/metabolism ; Mutation ; Myopathies, Structural, Congenital/genetics ; Neurons/metabolism ; Synaptic Transmission
    Chemical Substances Dynamin II (EC 3.6.5.5) ; DNM2 protein, mouse (EC 3.6.5.5)
    Language English
    Publishing date 2023-04-16
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80371-6
    ISSN 1365-2990 ; 0305-1846
    ISSN (online) 1365-2990
    ISSN 0305-1846
    DOI 10.1111/nan.12918
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Much more than hooked: Setal adaptations for camouflage in Macrocoeloma trispinosum (Latreille, 1825) (Crustacea: Decapoda: Brachyura).

    Lianos, Laira / Mollemberg, Michelle / Colavite, Jessica / Lopes E Silva, Amanda / Zara, Fernando José / Santana, William

    Arthropod structure & development

    2021  Volume 66, Page(s) 101132

    Abstract: ... about the fixation of exogenous material on the carapace are explored. M. trispinosum has a complex setal apparatus ...

    Abstract Several majoid crabs are known to adhere exogenous materials to their bodies, a behaviour called decoration. Until now, the adhesion of exogenous materials to the body is most attributed to the well-known hooked setae. Here, we analysed the carapace of Macrocoeloma trispinosum (Latreille, 1825) under light and electron microscopy to study the different mechanisms allowing majoid crabs to decorate themselves. Five setal types are described here, of which four for the first time: velvet type I, velvet type II, depressa and cattail seta. These setae are morphologically and histologically detailed, and new hypotheses about the fixation of exogenous material on the carapace are explored. M. trispinosum has a complex setal apparatus for the adhesion of the decoration, with tegumental ducts along the shaft of most setae. These tegumental ducts are connected to glands formed by large cells arranged radially (rosette or acini) at the base of the setae, in the connective tissue, just below the epithelium. We could observe these glands in different stages of maturation, and no valve-like structure was observed, which may indicate a continuous flow of protein secretion that could serve as an adhesive substance found in the apex of most setae. This is the first record indicating a potential chemical adhesion mechanism aiding the masking process in decorator crabs.
    MeSH term(s) Animal Shells ; Animals ; Brachyura/anatomy & histology ; Sensilla
    Language English
    Publishing date 2021-12-01
    Publishing country England
    Document type Journal Article
    ZDB-ID 2001498-3
    ISSN 1873-5495 ; 1467-8039
    ISSN (online) 1873-5495
    ISSN 1467-8039
    DOI 10.1016/j.asd.2021.101132
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.

    Liu, Shiqin / Chai, Timothy / Garcia-Marques, Fernando / Yin, Qingqing / Hsu, En-Chi / Shen, Michelle / Shaw Toland, Angus Martin / Bermudez, Abel / Hartono, Alifiani B / Massey, Christopher F / Lee, Chung S / Zheng, Liwei / Baron, Maya / Denning, Caden J / Aslan, Merve / Nguyen, Holly M / Nolley, Rosalie / Zoubeidi, Amina / Das, Millie /
    Kunder, Christian A / Howitt, Brooke E / Soh, H Tom / Weissman, Irving L / Liss, Michael A / Chin, Arnold I / Brooks, James D / Corey, Eva / Pitteri, Sharon J / Huang, Jiaoti / Stoyanova, Tanya

    Cell reports. Medicine

    2024  Volume 5, Issue 2, Page(s) 101381

    Abstract: Neuroendocrine carcinomas, such as neuroendocrine prostate cancer and small-cell lung cancer, commonly have a poor prognosis and limited therapeutic options. We report that ubiquitin carboxy-terminal hydrolase L1 (UCHL1), a deubiquitinating enzyme, is ... ...

    Abstract Neuroendocrine carcinomas, such as neuroendocrine prostate cancer and small-cell lung cancer, commonly have a poor prognosis and limited therapeutic options. We report that ubiquitin carboxy-terminal hydrolase L1 (UCHL1), a deubiquitinating enzyme, is elevated in tissues and plasma from patients with neuroendocrine carcinomas. Loss of UCHL1 decreases tumor growth and inhibits metastasis of these malignancies. UCHL1 maintains neuroendocrine differentiation and promotes cancer progression by regulating nucleoporin, POM121, and p53. UCHL1 binds, deubiquitinates, and stabilizes POM121 to regulate POM121-associated nuclear transport of E2F1 and c-MYC. Treatment with the UCHL1 inhibitor LDN-57444 slows tumor growth and metastasis across neuroendocrine carcinomas. The combination of UCHL1 inhibitors with cisplatin, the standard of care used for neuroendocrine carcinomas, significantly delays tumor growth in pre-clinical settings. Our study reveals mechanisms of UCHL1 function in regulating the progression of neuroendocrine carcinomas and identifies UCHL1 as a therapeutic target and potential molecular indicator for diagnosing and monitoring treatment responses in these malignancies.
    MeSH term(s) Male ; Humans ; Ubiquitin Thiolesterase/genetics ; Ubiquitin Thiolesterase/metabolism ; Carcinoma, Neuroendocrine/drug therapy ; Carcinoma, Neuroendocrine/genetics ; Small Cell Lung Carcinoma ; Lung Neoplasms/diagnosis ; Lung Neoplasms/drug therapy ; Membrane Glycoproteins
    Chemical Substances Ubiquitin Thiolesterase (EC 3.4.19.12) ; POM121 protein, human ; Membrane Glycoproteins ; UCHL1 protein, human
    Language English
    Publishing date 2024-01-19
    Publishing country United States
    Document type Journal Article
    ISSN 2666-3791
    ISSN (online) 2666-3791
    DOI 10.1016/j.xcrm.2023.101381
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Internal dose of vanadium in rats following repeated exposure to vanadyl sulfate and sodium orthovanadate via drinking water.

    Harrington, James M / Haines, Laura G / Levine, Keith E / Liyanapatirana, Chamindu / Essader, Amal S / Fernando, Reshan A / Robinson, Veronica G / Roberts, Georgia K / Stout, Matthew D / Hooth, Michelle J / Waidyanatha, Suramya

    Toxicology and applied pharmacology

    2021  Volume 412, Page(s) 115395

    Abstract: Vanadium is a ubiquitous environmental contaminant that exists in multiple oxidation states. Humans are exposed to vanadyl ( ... ...

    Abstract Vanadium is a ubiquitous environmental contaminant that exists in multiple oxidation states. Humans are exposed to vanadyl (V
    MeSH term(s) Administration, Oral ; Animals ; Body Burden ; Drinking Water ; Female ; Gastric Juice/chemistry ; Gastrointestinal Absorption ; Intestinal Secretions/chemistry ; Liver/metabolism ; Male ; Oxidation-Reduction ; Rats, Sprague-Dawley ; Tissue Distribution ; Toxicokinetics ; Vanadates/administration & dosage ; Vanadates/blood ; Vanadates/pharmacokinetics ; Vanadates/toxicity ; Vanadium Compounds/administration & dosage ; Vanadium Compounds/blood ; Vanadium Compounds/pharmacokinetics ; Vanadium Compounds/toxicity ; Rats
    Chemical Substances Drinking Water ; Vanadium Compounds ; Vanadates (3WHH0066W5) ; vanadyl sulfate (6DU9Y533FA)
    Language English
    Publishing date 2021-01-06
    Publishing country United States
    Document type Comparative Study ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, N.I.H., Intramural
    ZDB-ID 204477-8
    ISSN 1096-0333 ; 0041-008X
    ISSN (online) 1096-0333
    ISSN 0041-008X
    DOI 10.1016/j.taap.2021.115395
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top